Meeting
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
Authors
David S. Hong
University of Texas MD Anderson Cancer Center, Houston, TX
David S. Hong , Alexander E. Drilon , Daniel Shao-Weng Tan , Jessica Jiyeong Lin , Shivaani Kummar , Raymond S. McDermott , Jordan Berlin , Antoine Italiano , Ulrik Niels Lassen , Serge Leyvraz , Makoto Tahara , Ricarda Norenberg , Domnita-Ileana Burcoveanu , Nicoletta Brega , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT02576431, NCT02122913, NCT02637687
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3141)
DOI
10.1200/JCO.2023.41.16_suppl.3141
Abstract #
3141
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon
Poster
2022 ASCO Annual Meeting
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
First Author: Leo Mascarenhas
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
First Author: Alexander E. Drilon